Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560


Company Overview

Webcast ImageWebcast
Pacira Pharmaceuticals, Inc. Conference Call (Replay)
07/25/17 at 8:30 a.m. ET
Pacira Pharmaceuticals, Inc. Conference Call
Tuesday, July 25, 2017 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgery centers.
Stock Quote
PCRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.73 (1.85%)
Data as of 07/28/17 12:31 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
07/26/17Pacira Announces Publication of Phase 4 Study of EXPAREL in Patients Undergoing Total Knee Replacement in The Journal of Arthroplasty
PILLAR study demonstrated a 78 percent decrease in opioid consumption and significantly better pain control with infiltration of EXPAREL plus bupivacaine versus bupivacaine alone Ten percent of patients in the EXPAREL arm required no opioids for pain control PARSIPPANY, N.J., July 26, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the publication of its Phase 4 PILLAR study of EXPAREL® (bupivacaine liposome injectable suspension) in total knee arthroplast... 
Printer Friendly Version
07/25/17Pacira Pharmaceuticals Announces Timing for Second Quarter 2017 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., July 25, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Wednesday, August 2, 2017. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call from Pacira will be Dave Stack, chairman and chief executive officer, and other members of the company’s senior management team. The call can be accessed by dialin... 
Printer Friendly Version
07/25/17Pacira Announces Topline Phase 3 Results for EXPAREL® as a Single-dose Nerve Block
Upper extremity study showed that EXPAREL significantly reduces pain scores and opioid use Lower extremity study defined safety and pharmacokinetic profile through 120 hours Timing for resubmission of supplemental New Drug Application remains on track Conference call scheduled for today at 8:30 AM ET PARSIPPANY, N.J., July 25, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the completion of two Phase 3 placebo-controlled studies evaluating the effica... 
Printer Friendly Version
06/15/17Pacira Pharmaceuticals Appoints Mark I. Froimson, M.D., to Board of Directors
PARSIPPANY, N.J., June 15, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of Mark I. Froimson, M.D. to its board of directors. Dr. Froimson is currently serving as the President of the American Association of Hip and Knee Surgeons (AAHKS). Previously, he was the Executive Vice President and Chief Clinical Officer of Trinity Health, a major national non-profit Catholic healthcare system comprising 93 hospitals in 22 states. “Mark’s deep cl... 
Printer Friendly Version

Corporate Presentation

Corporate Presentation
Upcoming EventsMore >>
08/02/17 8:30 a.m. ET
Q2 2017 Pacira Pharmaceuticals, Inc. Earnings Conference Call
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Pacira Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Contact Investor Relations:
Susan Mesco
(973) 451-4030